Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
- Cleveland Clinic-Weston — Weston, Florida
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
- Sacred Heart Hospital — Pensacola, Florida
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Jupiter Medical Center — Jupiter, Florida
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Florida: - Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach, Florida
- Sylvester Comprehensive Cancer Center- Doral — Doral, Florida
- Sylvester Comprehensive Cancer Center - Hollywood — Hollywood, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Florida: - AdventHealth Medical Group Blood & Marrow Transplant at Orlando — Orlando, Florida
- Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in Florida: - Advanced Research — Coral Springs, Florida
- Florida Cancer Specialists - South — Fort Myers, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- Florida Cancer Specialists - East — West Palm Beach, Florida
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Florida: - Sylvester Comprehensive Cancer Center — Coral Gables, Florida
- Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Florida: - Memorial Healthcare System — Hollywood, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Florida: - Mayo Clinic Hospital Jacksonville /ID# 263324 — Jacksonville, Florida
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230 — Jacksonville, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Florida: - Mayo Clinic Florida — Jacksonville, Florida
- Tampa General Hospital — Tampa, Florida
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
- Cleveland Clinic — Weston, Florida
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Florida: - Blood & Marrow Transplant Center, Florida Hospital Medical Group — Orlando, Florida
- Moffitt at Memorial Healthcare System — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dex…
Sponsor: Pfizer
NCT ID: NCT05020236
Sites in Florida: - Sylvester Comprehensive Cancer Center - Aventura — Aventura, Florida
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables, Florida
- Sylvester Comprehensive Cancer Center - Coral Springs — Coral Springs, Florida
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach, Florida
- Sylvester Comprehensive Cancer Center - Hollywood — Hollywood, Florida
Phase 3 Recruiting Industry
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in Florida: - GSK Investigational Site — Englewood, Florida
- GSK Investigational Site — Lady Lake, Florida
- GSK Investigational Site — Pembroke Pines, Florida
- GSK Investigational Site — Saint Augustine, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in Florida: - Baptist MD Anderson Cancer Center — Jacksonville, Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida
- Local Institution - 0228 — Orlando, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07258511
Sites in Florida: - Florida Cancer Specialists & Research Institute — Fort Myers, Florida
Phase 3 Recruiting Industry
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05730036
Sites in Florida: - University of Florida Division of Sponsored Programs — Gainesville, Florida
Phase 3 Recruiting Industry
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05438043
Sites in Florida: - University of Miami Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in Florida: - GC2202 Study Site 103 — St. Petersburg, Florida
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Florida: - Florida Cancer Specialists North / Sarah Cannon Research Institute — Altamonte Springs, Florida
- University of Miami/Sylvester Cancer Institute - Aventura — Aventura, Florida
- Florida Cancer Specialists South / Sarah Cannon Research Institute — Bonita Springs, Florida
- Florida Cancer Specialists South / Sarah Cannon Research Institute — Bradenton, Florida
- Florida Cancer Specialists North / Sarah Cannon Research Institute — Brandon, Florida
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Florida: - Mayo Clinic in Florida — Jacksonville, Florida
- Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in Florida: - Research Site — Jacksonville, Florida
- Research Site — Miami, Florida
- Research Site — Tampa, Florida
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in Florida: - Life Clinical Trials - Coral Springs- Site Number : 8400055 — Coral Springs, Florida
- Center for Rheumatology, Immunology and Arthritis- Site Number : 8400031 — Fort Lauderdale, Florida
- Mayo Clinic in Florida- Site Number : 8400002 — Jacksonville, Florida
- The Oncology Institute of Hope & Innovation - Lakeland- Site Number : 8400054 — Lakeland, Florida
- D&H Pompano Research Center- Site Number : 8400049 — Margate, Florida
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Florida: - University of Miami — Miami, Florida
- Miami Cancer Institute — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in Florida: - Cancer Specialists of North Florida — Jacksonville, Florida
Phase 2 Recruiting Academic/Other
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT05972135
Sites in Florida: - Florida Cancer Specialists — Lake Mary, Florida